Prostarm Q2 FY27: consol PAT -27% YoY to ₹6.1 Cr on 82% revenue surge, margins compress
PAT -26.52% YoY · revenue +82.07% · margins compressing
₹120.01 Cr
+82.07% YoY
₹6.07 Cr
-26.52% YoY
4.99%
-7.3pp YoY
₹1.03
Prostarm Info Systems' consolidated revenue for Q2 FY27 (quarter ended September 30, 2026) came in at ₹120.01 Cr, up a sharp 82.1% year-on-year from ₹65.92 Cr and 57.8% sequentially from ₹76.05 Cr. But profitability moved the other way: consolidated PAT fell 26.5% YoY to ₹6.07 Cr from ₹8.27 Cr, even though it rose 32.6% quarter-on-quarter from ₹4.58 Cr. Read YoY-first, this is a profit decline dressed up in a revenue surge — net margin compressed to roughly 5.1% from 12.3% a year ago. Standalone PAT was ₹6.34 Cr on revenue of ₹119.46 Cr, close to the consolidated number, confirming the three BESS/energy subsidiaries remain immaterial to the group's bottom line for now. No exceptional items appear in either statement, so both YoY figures are reported, like-for-like.
Q2 FY-2027 vs prior quarters
The margin bridge is visible in the expense lines: purchase of stock-in-trade — a proxy for lower-margin EPC/trading volumes — jumped to ₹95.04 Cr from ₹24.81 Cr a year ago (+283%), while cost of material consumed actually fell (₹15.88 Cr vs ₹20.25 Cr), pointing to a revenue mix shift away from in-house manufacturing toward trading/execution-led business. Finance costs more than doubled to ₹2.04 Cr from ₹0.88 Cr as borrowings rose to fund working capital. The net effect: EBITDA-level margin fell to about 9.3% from 17.0% YoY (versus 8.5% last quarter), and net margin is running well below management's own FY27-end target of 8.5-9% PAT margin and 12-13% EBITDA margin, set out on the August 2026 concall.
The stock went into the print at ₹136.3, up 3.8% over the past month of trading.
FY27 targets minimum 25% revenue growth (maintained). EBITDA margins 12–13% by year-end, PAT margins 8.5–9% (upper end cut from prior 9.5%). Working capital to reach 120–150 days by March 2027; operating cash flow expected positive by FY27-end.
— This quarter: missed
On revenue, the company remains comfortably ahead of its guided 'minimum 25% growth' for FY27 — H1 FY27 consolidated revenue is up 62.2% YoY to ₹196.06 Cr — but on margins it is tracking well short of plan with two quarters left in the year. There is no sell-side consensus on record for Prostarm (no analyst coverage found), so vs-street is unknown; this read is benchmarked only against the company's own prior guidance. H1 FY27 operating cash flow was negative ₹17.77 Cr (versus negative ₹12.74 Cr in H1 FY26) as inventory and receivables continue to build, running counter to management's stated goal of positive operating cash flow by FY27-end and its 120-150 day working-capital target for March 2027. The quarter's corporate actions — a ₹42.61 Cr preferential warrant allotment (28.98 lakh warrants) completed in October 2026 after BSE/NSE approvals, alongside cancellation of a BESS project MoU in September 2026 — show capital being raised even as working capital stays stretched; no press release accompanied this result to corroborate management's own framing.
W1
EBITDA margin needs to rise from ~9.3% (Q2 FY27) to management's guided 12-13% by FY27-end — watch H2 trajectory.
W2
PAT margin needs to climb from ~5.1% to the guided 8.5-9% band by March 2027.
W3
Operating cash flow guided positive by FY27-end versus a ₹17.77 Cr negative H1 FY27 print — watch working-capital days against the 120-150 day target.
Strong order book, severe margin compression—growth hollow without profitability recovery
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Maintained 25% growth, 12–13% EBITDA guidance from Q1 FY27 call, but delivered margins (7.83% Q2, 8.16% H1) fall well short. PAT decline despite revenue surge is a red flag.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Prostarm delivered 82% revenue growth on a strong order book, but PAT collapsed 26.6% YoY due to cost inflation, freight headwinds, and low-margin BESS developer orders. Management claims margin recovery to 12–13% EBITDA by year-end, but H1 sits at 8%, operating cash flow is still negative, and working capital at 192 days. The new facilities (Jhajjar, Bakrol) offer structural upside if execution delivers, but near-term profitability recovery is unproven.
₹120 Cr
Revenue · +82.1% YoY₹6.1 Cr
Reported PAT · −26.6% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
EBITDA margins 12–13% by FY27 year-end
OVERSTATEDQ2 at 7.83%, H1 at ~8.16% (₹16 Cr / ₹196 Cr)
PAT margins 8.5–9% guidance
OVERSTATEDQ2 at 5.08%, H1 at 5.46% (₹11 Cr / ₹196 Cr)
Order book ₹1,121 Cr provides visibility
MET97 projects, 78% government (less price pressure but higher WC)
Margin compression temporary, due to costs, mix
METFreight doubled, low-margin BESS orders, facility startup cost—valid but no timeline given
Operating cash flow to turn positive by FY27-end
PartialStill negative at ~₹17 Cr (Sept end). March collections flagged but not guaranteed
Earnings quality
What changed since the last call
Margin guidance maintained but gap widened
DowngradeGuidance: 12–13% EBITDA by year-end. Q2 delivered 7.83%, H1 at ~8.2%. Gap of ~4–5 ppts suggests guidance out of reach or phased into next year.
BESS orders now 81% of book by value
NewOrder mix shifted heavily BESS developer (₹854 Cr / ₹1,121 Cr total). Developer model lower margin than EPC, but government tailwind strong (VGF scheme).
Operating cash flow still negative
DowngradeH1 FY27 target was positive. At Sept end: ~–₹17 Cr (improving from –₹49 Cr in Mar). Collections and billing traction noted but not yet breakeven.
New manufacturing facilities now live
UpgradeJhajjar (1.2 GWh BESS) and Bakrol (UPS, 3k units/day) operational. Expected to drive FY28+ margins and reduce third-party dependencies.
The Q&A
Paras Cheda (analyst, PurpleOne Vertex) pressed hard on margin compression: 7.83% Q2 vs 13–14% guidance, PAT down 27% despite revenue growth. Mgmt was defensive, blamed freight doubling, low-margin order execution, and facility startup costs. When asked for year-end margin recovery, mgmt hedged: 'moderate' to 12% by year-end, not guaranteed. Analysts held mgmt to 25% growth guidance but remained skeptical on margin timeline.
Margin compression — Paras Cheda, PurpleOne Vertex Ventures
PartialTemporary, due to cost inflation (freight almost doubled, elevated input costs), low-margin BESS developer execution, and facility startup overhead. Future billing should normalize; looking to ₹500 Cr EBITDA, >11% by year-end.
FY27 guidance — Paras Cheda, PurpleOne Vertex Ventures
Dodged12–13% EBITDA: should return; >11% minimum. PAT 8.5–9%: 'PAT growth would be there.' Cautious language; no firm commitment on year-end achievement.
Working capital and OCF — Paras Cheda, PurpleOne Vertex Ventures
PartialImproving. Collections accelerating (₹75 Cr in Oct, more by Dec). WC elevated due to inventory for Bakrol facility startup, new capex, and GST credit timing. By FY27-end, should trend positive. Conscious working capital blockage.
Jhajjar facility capacity — Dheraj Patel, Individual Investor
Answered1.2 GWh single-shift; can scale to 3 GWh/hour in 3-shift. Assembly-focused plant; cell procurement external. Lithium cells to remain imported unless backward integration, which is not planned yet.
Bakrol UPS facility — Aarav Jain, Individual Investor
Answered3,000 units/day capacity. Can generate ₹500–600 Cr revenue/year. Full-fledged plant with lithium integration. Gradual ramp toward factory-based assembly; benefits by FY28–29.
BESS order profitability — Paras Cheda, PurpleOne Vertex Ventures
PartialMargin under pressure due to lithium and DC block cost increases. Equity IRR dropped. Actively negotiating down-sell with 6–7 industry players; may close one soon. Benefits include mover revenue + margin recovery.
FY28 guidance — Paras Cheda, PurpleOne Vertex Ventures
Dodged25% growth is minimum, 'hard' target. But revenue may segment shift: some solar EPC down, BESS up if export, UPS up. EBITDA margin back to 12–13% possible, PAT 8.5–9%. Facility ramp will help.
BESS market competition — Devan Shah, Eternal Capital
PartialCommodity pressure yes, but Prostarm has local domestic content advantage (India banned solar imports, will ban battery imports). Local manufacturing and solution provider focus (not just EPC) = differentiation. But execution remains key.
Guidance
FY27 minimum 25% growth (maintained from Q1 FY27)
HighOrder book ₹1.1 Cr provides multi-quarter visibility. H1 achieved 62% growth; likely to moderate Q3–Q4 but 25% minimum should hold.
EBITDA 12–13% by FY27 year-end
LowCurrent H1 at 8.2%. Gap of ~4–5 ppts suggests either (a) heavy ramp in H2, or (b) guidance slip to next year. Mgmt hedged with 'should' language.
PAT margin 8.5–9% (from prior 9.5%)
LowH1 at 5.46%. Recovery depends on EBITDA improvement, finance costs, and tax rate. Mgmt said 'growth path' but no timeline.
No explicit capex guidance given
MediumFacilities now operational (Jhajjar, Bakrol); incremental capex likely modest. Debt will increase to support inventory and WC during ramp.
Risks the call surfaced
Margin compression
HighQ2 EBITDA margin 7.83% vs 12–13% guidance. Freight costs almost doubled, low-margin BESS orders, facility startup costs. Recovery path unclear.
Working capital stress
MediumWC cycle at 192 days (up from 185); inventory for Bakrol, receivables from government lag (₹257 Cr outstanding at H1, improved to ₹201 Cr by Oct). OCF negative at ~₹17 Cr Sept.
Order execution risk
MediumBESS developer orders (₹854 Cr / 76% of book) have thin margins due to lithium/DC cost inflation. 2–3 year project cycles; down-sell negotiations ongoing but outcomes uncertain.
Guidance credibility
Medium12–13% EBITDA guidance maintained from Q1, but H1 delivery at 8.2%. Gap of ~4–5 ppts. Mgmt hedged recovery to 'should' language, suggesting uncertainty.
Government order concentration
Low78% of order book from government customers; benefits from VGF/policy support but exposes to bidding and payment cycle risk.
Management
Score 6/10. CFO detailed on numbers but defensive on margins. CEO bullish on structural opportunities but vague on near-term recovery timeline. Limited transparency on BESS down-sell discussions and profitability trajectory. Strong order intake (₹1.1 Cr book, 23% YoY growth). But margin management poor: revenue up 82%, PAT down 27%. Facility ramp (Jhajjar, Bakrol) on track, but startup costs weighing down current quarter.
1 · Dec 2026 – Mar 2027
Collections from government (₹257 Cr outstanding → down to ₹201 Cr by Oct), ₹75 Cr collected in Oct alone
2 · FY28 (3+ years)
Jhajjar 1.2 GWh at 25–30% utilization; Bakrol 500–600 Cr revenue potential at higher margins
3 · Next FY
Facility ramp absorbs overhead, margin recovery to 8.5–9% PAT if BESS volume holds
The new facilities (Jhajjar, Bakrol) offer structural upside if execution delivers, but near-term profitability recovery is unproven.